VEN+AZA+Modified BUCY

DRUG2 trials

Sponsors

The First Affiliated Hospital of Soochow University

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAllogeneic Hematopoietic Stem Cell TransplantationMyelodysplastic Syndrome

Phase 2

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT

RecruitingNCT05809167

The First Affiliated Hospital of Soochow UniversityAcute Lymphoblastic Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation

Start: 2022-01-20End: 2026-01-20Target: 55Updated: 2023-04-12

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

RecruitingNCT05823714

The First Affiliated Hospital of Soochow UniversityAcute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndrome

Start: 2022-01-20End: 2026-01-20Target: 70Updated: 2023-04-21

Related Papers

VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial

Blood2024-11-05

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes

Blood2023-11-02